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A B S T R A C T
Purpose: To evaluate the electroclinical features, treatment effectiveness, and outcome of 59 patients
with epileptic encephalopathy with electrical status epilepticus during sleep.
Methods: Medical-ﬁles of 59 patients with electrical status epilepticus during sleep were retrospectively
evaluated for data concerning: history, physical and neurological examinations, sleep and awake EEG’s,
psychometric tests and brain MRI.
Results: A total of 31 boys and 28 girls were identiﬁed. Patients were evaluated in two groups:
symptomatic/structural and idiopathic group. There was no signiﬁcant difference between the
etiological groups in term of mean age at ESES onset, mean interval between the ﬁrst seizure and the
onset of ESES. The mean age at seizure onset was earlier in the symptomatic/structural group than
the idiopathic ones. The mean follow-up time after the ESES onset was 4.5 years for all patients. The
most effective antiepileptic drugs in our series were clobazam and levetiracetam. In refractory
patients, steroid treatment was found effective during the early course of the disease. In the
idiopathic group, cognitive decline has improved. However in the symptomatic group, patients did
not respond to the treatment and cognitive deterioration did not improve in one third of the group.
Conclusion: The long-term outcome of ESES is highly variable and usually depends on etiology and the
duration of ESES. The most efﬁcious antiepileptic drugs in our study are clobazam and levetiracetam.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epileptic encephalopathy with electrical status epilepticus
during sleep (ESES) is a condition in which the epileptiform
abnormalities themselves contribute to the progressive distur-
bance in cognitive function. According to the last ILAE proposal, it
is deﬁned as an age related, self limited disorder characterized as
epilepsy with different seizure types, neurophysiological and
motor impairment and typical EEG ﬁndings of continuous epileptic
activity occupying 85% of non-rapid eye movement (REM) sleep.
Although spike-wave activities are offered to occur during at least
85% of non-REM sleep in this classic deﬁnition, in patients with a
well matched clinical presentation lower cut off rates have been
accepted in subsequent studies [1,2].
ESES mostly occur in children with symptomatic or structural
epilepsy associated with diffferent types of organic brain lesions. It* Corresponding author. Tel.: +90 312 2025608.
E-mail address: mehmetarhan@gmail.com (E. Arhan).
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which is seen Landau-Kleffner syndrome. Benign childhood
epilepsy with centrotemporal spikes (BCECTS) sometimes has
atypical course, with ESES and cognitive deterioration [1].
Although usually the prognosis of epilepy in ESES is favorable,
the main concern is the deterioration of one or more cognitive
functions. Knowledge about clinical spectrum has broadened and
it is now known that ESES may be responsible not only for acquired
aphasia but behavioral and/or psychomotor decline with or
without motor symptoms have also been described in patients
with ESES [3–7]. However, there is currently limited data on the
neurophysiological evaluation of these patients.
In addition to the lack of data on neurophysiological evaluation,
there are several unresolved questions regarding the treatment
modalities in ESES. Various antiepileptic drugs (AED) such as
valproate (VPA), ethosuximide (ESM), levetiracetam (LEV) and
benzodiazepines have been tried. Recently classic and new AED’s
have been switched to benzodiazepines and ethosuximide [3,8,9]. In
refractory patients, corticosteroids, gama globulins and the keto-
genic diet have also been used as therapuetic alternatives. Despiteserved.
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is not yet a standardized therapy for ESES and treatment strategies
have not been reported in a large group of patients.
Yet there is, so far, limited number of studies regarding the
long-term neurophysiological outcome and treatment modalities
in a large group of patients with the ESES. Therefore, we aimed to
describe the clinical features, etiology, the impact of etiology on
prognosis, the treatment and prognosis of 59 patients with the
ESES syndrome.
1.1. Patients and methods
The present study was a descriptive, retrospective study of 59
consecutive patients with the ESES syndrome followed between
2006 and 2013. Inclusion criteria included:
1. Onset with focal or apparently generalized seizures and focal
EEG discharges.
2. Further appearance of atypical absences, and myoclonic, atonic
(with or without epileptic falls), and/or generalized seizures.
3. Cognitive impairment and/or behavioral disturbances related to
the ESES period.
4. ESES occurring in more than 85% of the non-REM sleep, however,
a lower percentage between 85% and 30% was also considered
[3,4,10,11].
Myoclonic astatic epilepsy with cognitive deterioration, Lennox
Gastaut syndrome not fulﬁlling the criteria for the ESES syndrome
and focal epilepsies with secondary bilateral synchronies not
fulﬁlling the criteria for the ESES syndrome were excluded.
Medical-ﬁles were retrospectively evaluated for data concern-
ing: history, physical and neurological examinations, sleep and
awake EEG’s, psychometric tests and brain MRI. Patients with an
underlying etiology were classiﬁed as symptomatic/structural
while others were classiﬁed as idiopathic. Follow up EEG’s under
different treatment regimens were evaluated along with neuro-
psychological data.
All patients underwent at least three prolonged sleep EEGs
(more than 1 h), and 20 of these 59 patients underwent all-night
video-EEG in addition to the routine EEG recordings. The spike-
wave index (SWI) on the non-REM sleep EEG during the ESES
period was visually calculated based on the total number of
spike-waves per unit of time or based on the information
provided by the epileptologists in the clinical charts. The ranges
of the index considered were: >85%, 50–85%, and 30–50%.
Prolonged sleep EEG’s were repeated at least two times a year. All
59 patients underwent at least one magnetic resonance imaging
(MRI) study.
Fifty-two patients underwent neuropsychological assessment
using the WISC-R test, or the Stanford–Binet scale when the WISC-R
test could not be administered. Forty-one patients were evaluated
by consecutive neuropsychological tests. Previous neuropsycholog-
ical tests have been performed in 31 patients. In addition, parents,
teachers and caregivers were interwieved regarding deterioration
and improvement and with respect to clinical judgment by the
authors A.S and E.A, clinical improvement was graded as full, more
than 75%, more than 50% and less than 50%.
The estimated onset of the ESES period was deﬁned as the time
from the onset of regression; the end of the ESES period was
deﬁned as the time of signiﬁcant functional improvement
coinciding with the disappearance of ESES on sleep EEG. Response
to drug treatment was evaluated and deﬁned as; seizure freedom
and repeated sleep EEG’s with complete normalization or
disappereance of the ESES, signiﬁcant reduction in seizure
frequency and a more than 75% of improvement of the SWI,
50–74% seizure reduction and a more than 50% improvement ofthe SWI, 30–49% seizure reduction and a more than 30%
improvement of the SWI and no response.
1.2. Statistics
The association between age at seizure onset, age at ESES onset,
duration of ESES, SWI and outcome were analyzed by Student’s
t-test. The associations between etiology and epilepsy type and
outcome were examined by Fisher’s exact test. SPSS for Windows,
v.15 (SPSS, Chicago, IL, USA) was used for the analysis. P-value
<0.05 was considered statistically signiﬁcant.
2. Results
2.1. General clinical features
There were a total of 59 patients (31 boys and 28 girls) with the
ESES syndrome recruited from the Gazi University Department of
Pediatric Neurology between 2006 and 2013. Six patients (10.2%)
had a family history of epilepsy and two (6.8%) of febrile seizures.
Seventeen patients had perinatal insult (10 perinatal asphxia, two
intrauterine infections, four neonatal seizures, one prematurity
and one neonatal hypoglycemia). Two patients (3.4%) had
antedecedents of West syndrome.
ESES evolved from several different probable etiologies.
Nineteen (32.2%) patients had benign partial epilepsies of
childhood, of whom 14 had benign childhood epilepsy centro-
temporal spikes (BCECTS), ﬁve had benign childhood epilepsy with
occipital paroxsyms. One patient had temporal lobe epilepsy.
Eleven patients had cerebral palsy, seven had hemiparesis and four
had spastic diplegia.
All patients had magnetic resonance imaging and 20/59 were
abnormal. Abnormal imaging ﬁndings were; hydrocephalus in
three patients, cortical atrophy in three, periventricular leucoma-
lasia in two, encephalomalasia in three, porencephaly in three,
polymicrogyria in one, occipital hyperintensity in one, thalamic
lesion in three and hypocampal atrophy in one patient.
2.2. Seizures and EEG ﬁndings before the onset of ESES
Fifty-three of the 59 patients had experienced seizures before
the onset of the ESES. The seizures were complex focal in 29
(49.2%) of these patients. Nine (15.3%) patients had apparently
generalized seizures, ﬁve (8.5%) patients had secondary general-
ized focal seizures. Atypical absences were found in three
(5.1%) patients. Five (8.5%) patients had myoclonic seizures and
one (1.7%) patient had spazm. Six (10.2%) patients had tonic
seizures.
There were 31 patients (19 males) in the symptomatic/
structural group. The mean age at seizure onset was 3.78  2.08.
The current mean age of this group is 11.45  3.66 years. Time
between the ﬁrst seizure and the onset of the ESES is 3.2  2.17
years.
In the idiopathic group, 12 of the 28 patients were male. The
mean age at seizure onset was 5.6  2.69. The time lag between
the onset of epilepsy and the onset of ESES was 3.1  1.36 years.
There was no signiﬁcant difference between the etiological
groups in term of mean age at ESES onset, mean interval between
the ﬁrst seizure and the onset of ESES. The mean age at seizure
onset was earlier in the symptomatic/structural group than the
idiopathic ones.
The awake EEG recordings revealed focal epileptiform
activity in 37 patients (62.7%), generalized in 7 (11.9%) and
multifocal in 15 (25.4%) patients. EEG background activity
showed diffuse slowing in 13 (22%) patients in the symptomatic/
structural group.
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The mean age at ESES onset was 6.4  1.92 years, with no
signiﬁcant difference between the etiological groups. The
mean duration of ESES was 21.2  10.03 months (range 3–26
months).
During ESES, 37 (62.7%) patients continue to experience
seizures. During follow-up, new seizure types occurred in 30
patients (50.8%). These seizures were absences in 14 (23.7%), atonic
seizures in 15 (25.4%) and negative myoclonus in 3 (5%).
During the ESES phase, the SWI was >85% in 44 patients, 50–
85% in 13 and 30–50% in 2 patients. No signiﬁcant clinical
difference was seen regarding the percentage of the SWI between
the two groups. The characteristics of sleep EEG during the ESES
were as follows: focal epileptic activity in 17, secondary
generalized epileptic activity in 23, generalized epileptic activity
in 19. In the symptomatic group, asymmetric background activity
was seen in 2, polyspikes were seen in 3 and diffuse voltage
attenuation was seen in 1 patient. In the idiopathic group, there
was not any background EEG abnormality. (Fig. 1a and b and Fig. 2a
and b).
Before the ESES phase, 21 of 59 (47.5%) patients had normal
development, these patients were all in the idiopathic group. In the
symptomatic group, 22 patients had mental retardation, one
patient has autism.
During the ESES phase, neurocognitive deﬁcits in the patients
were; intellectual deterioration in 24 (40.6%), verbal auditory
agnosia in 12 (20.3%), aphasia in 8 (13.5%), behavioral changes in 3
(5.1%), memory deﬁcits in 1 (1.7%), attention deﬁciency hyperac-
tivity disorder in 16 (%), aggresiveness in 20 (33.8%).
Table 1 shows the general features, seizures and EEG ﬁndings
before and during the ESES period of all patients.
2.4. Treatment response
Response to treatment was classiﬁed as:
(1) Seizure freedom and repeated sleep EEG’s with complete
normalization or disappereance of the ESES in 18 (30.5%)
patients.
(2) Signiﬁcant reduction in seizure frequency (more than 75%) and
a more than 75% of improvement of the SWI in 19 (32.2%)
patients.
(3) 50–74% seizure reduction and a more than 50% improvement of
the SWI in 13 (22%) patients.
(4) 30–49% seizure reduction and a more than 30% improvement of
the SWI in 2 (3.4%) patients.
(5) No response in 7 (11.9%) patients.
Outcome according to the EEG criteria to evaluate response was
as follows: normalization of the record (18), improvement of more
than 75% of SWI (17), improvement of more than 50% of SWI (12),
improvement of more than 30% of SWI (1); transformation of
generalized epileptic activity into focal activity (4), and no
response (7).
During the ESES phase, the following antiepileptic drugs did
not show any efﬁcacy: valproic acid in 17 patients, topiramate in 5
patients, carbamazepine in 7 patients, oxcarbazepine in 9
patients, clobazam in 3 patients, levetiracetam in 7 patients,
gabapentin in 2 patients. Three patients were resistant to
multidrug treatment.
Positive response was seen with the following antiepileptic
drugs, and other treatment options:
Clobazam (14 of 25 patients – 56%): Four received with valproic
acid, three received with levetiracetam, two patients with
immunoglobulins and one received in combination with steroids.One patient had a temporary response, after 4 years of clinical
response seizures recurred.
Levetiracetam (8 of 19 patients – 42%) Three patients had a
transient response. Two patients received with clobazam and two
received in combination with valproate.
Valproate (6 of 13 patients – 46%) Valproate alone had a
transient response only in two patients; both of these two patients
were in the idiopathic group. Four patients received with
clobazam, two patients received vith levetiracetam.
Steroids (6 of 14 patients – 42%): Steroid was tried if other
antiepileptic drugs failed in our patients and patients received
steroids in combination with the antiepileptic drugs. Two patients
showed a transient response and relapsed after 1 year. One patient
became steroid dependent.
Immunoglobulins (1 of 4 patients – 25%): Two patients received
immunoglobulins in combination with clobazam. One patient
showed a transient response.
Vagal nerve stimulation was performed in two patients. One
patient showed a transient response, she has a seizure reduction of
50% after 6 months of VNS but during follow-up her seizures
recurred. The other patient however showed a positive response in
combination with other antiepileptic drugs. He has a seizure
reduction of more than 75% after 4 months of VNS implantation
and after 3 years of VNS implantation, his seizure reduction is stil
more than 75%:
A transient response was seen in nine patients using; valproic
acid and clonazepam (two patients), valproic acid and lamotrigin
(one patient), levetiracetam (three patients), valproic acid (two
patients) and clobazam (one patient).
Notably, only four patients relapsed during follow-up. Three
patients were in the symptomatic group whereas one had atypical
centrotemporal epilepsy of childhood. Two of them had response
after clobazam was introduced. The other two had a transient
response to steroid treatment and relapsed after 1 year and one of
them became steroid dependent.
Treatments of the patients are summarized in Table 2.
2.5. Outcome
The mean follow-up time after the ESES onset was 4.5 years
(range, 1–6 years) for all patients. At the last control, 22 patients in
the idiopathic group were seizure free whereas only 8 patients in
the symptomatic group have become seizure free. Among 22
patients in the idiopathic group, ﬁve patients displayed focal and
two patients showed multifocal anomalies in EEG recordings. In
the symptomatic group, the EEG showed focal spikes in three,
multifocal spikes in ﬁve patients.
There was a signiﬁcant correlation between ESES duration and
cognitive deﬁcits at the last control. There were 36 patients with
ESES duration between 6 and 24 months, of these patients ﬁve did
not regain baseline cognitive level. Twenty-three patients had ESES
duration of more than 2 years, none of these patients regained
baseline cognitive levels.
In the idiopathic group, nearly all patients showed deﬁnitive
control of seizures and normalization of the EEG. The best results
were obtained in the rolandic group. Patients with hydrocephalus
had better cognitive outcome than the other symptomatic group.
During follow-up, patients with complete seizure control and in
patients having a more than 75% seizure reduction, cognitive
performance signiﬁcantly improved. Of the patients in the
idiopathic group, cognitive decline has improved outcomes and
treatment effectiveness was observed and they returned to normal
baseline cognitive levels. However in the symptomatic group,
cognitive deterioration did not improve in one third of the group.
Table 3 shows the cognitive outcome according to etiology and
SWI.
Fig. 1. (a) Ten-year-old boy with atypical centrotemporal epilepsy of childhood. Sleep EEG recording shows asymetric spike and wave discharges in more than 85% of slow
wave sleep; (b) EEG recording of the same patient after i.v steroid treatment.
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ESES is an electrographic pattern associated with focal and/or
generalized seizures and neurophysiological, cognitive and/or
motor impairment [12]. The criterian of ESES is not only a
mathematical index but also an EEG criterion. Although the
classical deﬁnition of ESES suggests SWI occurring between therange of 85–100% of non-REM sleep, later studies have accepted
lower threshold values since patients with a SWI < 85% have also
demonstrated neuropsychological regression [2–4,10,13–15].
Neuropsychological regression in patients with an SWI of less
than 85% has been demonstrated in previous studies [1–3,10]. In
their large series, Caraballo reported that psychomotor deteriora-
tion was observed even in a modest or not so continuous activation
Fig. 2. (a) Seven-year-old boy with thalamic lesion. Sleep EEG recording shows asymetric spike and wave discharges in more than 85% of slow wave sleep; (b) Axial FLAIR MRI;
lesion in the right thalamus (arrow).
Table 1
Summary of clinical data and electrophysiological ﬁndings before and during the ESES period in all patients.





























I˙diopathic 28 5.6  2.69 CFS, SGTCS Focal spıkes, multifocal
spikes generalized spikes




CFS, complex focal seizures; SGTCS, secondarily generalized tonic-clonic seizures; AA, atypical absences.
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Table 2
Summary of drug treatment.
Patient group No. of
patients





31 CBZ, VPA, TPM, OXC,
PB, LTG and combinations
VPA, LVT, CLB, GB iv
steroid, IVIG
3–26 months CLB, LVT, iv steroid, IVIG
Idıopathic 28 CBZ, VPA, OXC VPA, LVT, CLB, iv steroid 3–6 months CLB, LVT, iv steroid, IVIG
CBZ, carbaamzepine; VPA, valproic acid; TPM, topiramate; PB, phenobarbital; OXC, oxcarbazepine; LTG, lamotrigine; LVT, levetiracetam; CLB, clobasam; GB, gabapentin; IVIG,
intravenous immunoglobulin.
Table 3
Outcome according to etiology and SWI in our patients with ESES.
Groups SWI (%) (n) Outcome
Favorable Unfavorable
Symptomatic >85 (22) 15 7
Symptomatic 50–85 (5) 2 3
Symptomatic 30–50 (4) 2 2
Idıopathic >85 (16) All patients
Idıopathic 50–85 (8) All patients
Idıopathic 30–50 (4) All patients
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that even in patients with a lower SWI, cognitive abilities may be
disturbed. It appears thus mandatory to achieve neuropsychologi-
cal studies in ESES patients with a lower SWI with the assessment
of speciﬁc cognitive skills, particularly in order to improve
rehabilitation strategy. Our study has strenghtened the idea that
ESES is an epileptic encephalopathy with a broad range of SWI and
conﬁrmed that the electroclinical criteria for the ESES syndrome
should be revised.
In this study, we have analyzed the impact of ESES on long-term
neurophysiological outcome and treatment modalities in a large
group of patients with the ESES. In our series, two different
etiological groups emerged: symptomatic/structural group and
idiopathic group. The largest group in our series comprised
symptomatic/structural cases. In this group, there were 17 patients
with perinatal insults like perinatal asphxia, intrauterine infection,
and neonatal hypoglycemia. Presence of pre/perinatal insults have
been reported earlier by Scholtes, Liukkonen and Deg˘erliyurt et al.
[16–18]. Twenty patients in this group had malformations of
cortical development. Polymicrogyria and hydrocephalus are the
most commonly reported cortical malformations in the etiology of
ESES [3,19]. Thirty-eight percent of the patients were reported to
have polymicrogyria in the largest series. Horizontal cortical
lamination is preserved in polymicrogyria and this ensures the
rapid spread of spike-wave discharges [20]. Only patient with
polymicrogyria in our series was due to intrauterine cytomegalo-
virus infection. There were three patients with hydrocephalus in
our series. As distinct from the previous reports, there were three
patients with thalamic lesion in our series. The role of the thalamus
in the pathophysiology of generalized spike wave discharges, as in
ESES, has been shown in animal models [21]. Both cortex and
thalamus participate in the generation of spike-wave discharges,
although opinions differ on the relative importance and the need
for an intact thalamocortical circuit in the generation of these
discharges [22]. When normal circuitry is disturbed by a lesion, as
seen in the patients reported in our study, electrical ﬁring might be
altered. The association of ESES and thalamic lesion has been
emphasized in case reports previously [23–25]. This implies that
thalamic lesion alone may cause epilepsy and ESES with related
disruption of normal neurodevelopment.
It has been postulated that prolonged epileptic activity during
sleep as in ESES interferes with spike wave activity generating
mechanisms at the site of the epileptic focus and in consequence ofthis impairs the neural processes and, possibly, the local plastic
changes associated with learning and other cognitive functions
[26]. In this respect, cognitive involvement may also be prominent,
but a less frequent complaint of phenomena than seizures during
the stages of pre-ESES and ESES. We found that 40.6% of our
patients showed cognitive decline. Along with this decline, major
cognitive deﬁcits in our patients were language deterioration,
attention deﬁcit and hyperactivity, learning difﬁculties, aggre-
siveness and autistic-like behavior. Similar repertoire of cognitive
deﬁcits have been commented in previous studies [3,4,13,27].
Besides cognitive dsyfunction, motor disabilities like ataxia, ﬁne
motor dsyfunction, dsytonia, clumsiness were also seen in our
series. Caraballo et al. described loss of independent gait,
worsening of a unilateral deﬁcit, distortion in hand writing in
their series [3]. Fejerman and Seegmuller have attributed these
motor impairments to negative myoclonus in ESES patients
[27,28].
Our study constitutes an attempt to identify the predictors for
the long-term cognitive outcomes of patients with ESES. Early
onset seizures, appereance of new seizures during ESES period and
increase in seizure frequency, resistance to antiepileptic drugs
andsymptomatic/structural etiology group, longer duration of
ESES are proposed to predict pooroutcome in ESES patients
[3,4,29]. In our study, outcome depended on the etiology, duration
of ESES and early response to treatment.
Etiology was the main predictive factor in our series. The
idiopathic group had the most favorable course, with normal or
nearly normal cognitive outcome in 18 of 22 patients and in the
idiopathic group, patients with benign partial epilepsy with
centrotemporal spikes had an excellent prognosis. This is in
contrast with Saltık et al. outcomes [30]. In the symptomatic/
structural group, the patients with polymicrogyria had better
prognosis than the other structural etiologies. There was only one
patient with polymicrogyria. Therefore, we could not make an
analysis for this sole patient. Hydrocephalus is the second most
common etiology associated with ESES and usually has a good
prognosis if recognized early. In children with early-onset
hydrocephalus, particularly with behavioral and language dis-
turbances, and/or motor deterioration, ESES should be considered.
Periodic EEG recordings during sleep should be done in these
children. One other predictive factor for poor long-term neuro-
psychological outcome is the duration of ESES [17,31]. This may be
explained by the hypothesis that markedly abnormal neuronal
activity during a critical period of synaptogenesis results in
aberrant synapse formation [32]. In a study by Robinson et al. no
child with ESES persisting longer than 36 months had normal
language outcome [31]. Caraballo et al. found better neurophysio-
logical outcome in patient with a shorter duration of ESES [3]. The
duration of ESES in our patients ranged between 3 and 26 months
and we found a signiﬁcant correlation between duration of ESES
period and residual cognitive deﬁcits.
Our retrospective study includes patients that were not treated
by a standard algorithm, but rather subjected to treatment choices
made by the epileptologists on their personal intuition. The
response to treatment was not that favorable on the whole. The
E. Arhan et al. / Seizure 26 (2015) 86–9392most common antiepileptic drugs used for ESES include valproate,
ethosuximide, and levetiracetam [12]. Although we did not have an
algorithm, we have selected VPA for ﬁrst line AED for most of the
patients, based on previous retrospective reports however, we
could not conﬁrm observations of previous studies in which
valproic acid played a major role in the treatment of ESES [20,33].
We did somehow saw beneﬁt of valproic acid in some patients but
most of them failed. Ethosuximide and sulthiame are not available
in our country; therefore we could not try these drugs as the ﬁrst
line therapy for ESES.
We demonstrated a signiﬁcant effect of levetiracetam and
clobazam in treating ESESin our patients. The efﬁcacy of
levetiracetam and clobazam is supported by case reports in
theliterature [4,31,34–36]. Corticosteroids have shown improve-
ment in selected cases and, in some cases, lead to complete
resolution of ESES. Once ESES is recognized, usually during the
acute phase, corticosteroid treatment should be considered. In line
with previous sturides, steroid therapy was effective for short term
in our series [4,20,26]. Of those, two patients showed a transient
response and relapsed after 1 year. Liukkonen et al. reported
contrary results with steroids, even if given within the 1 year of
diagnosis [16]. We tried steroid therapy when other antiepileptic
drugs failed and patients received steroids with antiepileptic
drugs. Immunoglobulins are considered as a part of the therapuetic
protocol in patients with Landau-Kleffner syndrome and not
considered as an option in the treatment of ESES. Therefore only a
handful of patients treated with intravenous immunoglobulins
have been reported in the literature. Intravenous immunoglobulin
treatment was associated with improvements in 1 out of 4 patients
in our series. In another series, the neurocognitive function of 1 out
of 3 patients with ESES improved following the administration of
intravenous immunoglobulins [37]. However, there is probably a
publication bias of positive results, and the high cost and risk of
complications associated with immunoglobulins maketheir role in
the treatment of ESES unclear. In previous case reports, carbamaz-
epine, oxcarbazepine, phenobarbital, or phenytoin have been
reported to induce the appearance of electrical status epilepticus
during slow sleep; therefore these drugs should be avoided during
ESES [38,39].
The retrospective nature of this study was a major limitation to
our ability to precisely determine the results. Therefore, most of
the information obtained was based on the medical ﬁles of the
patients. Another issue was that the treatments are not readily
comparable because of the lack of a standard treatment algorithm.
Additional study design modiﬁcations can enhance the merit of our
study. Beyond these limitations, our study has several advantages
over previous studies, such as large number, a homogenous group
of patients with ESES, and long-term follow-up, covering different
aspects of clinical and electrophysiological outcome parameters.
Summary
This study conﬁrms that ESES is an epileptic encephalopathy
with a broad SWI. Patients with an SWI of >50% should be followed
up frequently along with neuropsychological assessments at
regular intervals. The impact of ESES on the development and
functional ability of children is signiﬁcant. Etiology seems to have
the major impact on long-term prognosis, as severe permanent
cognitive deterioration is rare in idiopathic cases, whereas patients
with symptomatic/structural epilepsy have considerably worse
long–term cognitive outcome. Children with hydrocephalus and
thalamic injury should be monitored cautiously for the evolution
of ESES. Duration of ESES also have a strong impact on the outcome.
According to our study, clobazam, levetiracetam and early steroid
treatment seem to be valuable switching options, in combination
with other antiepileptic drugs or alone, until more prospective dataon treatment modalities for ESES are available. For effective
management, it is crucial to have a standard algorithm for the
treatment of ESES. It is hoped that this information can provide a
model for further study and add to the existing data.
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